📈 economics

Demand for Off-Patent Drugs and Sequential Price Competition with Heterogeneous Consumers: A Reappraisal of the Generic Competition Paradox

This paper reappraises the Generic Competition Paradox by modeling sequential price competition with heterogeneous and misinformed consumers, demonstrating that while brand prices remain higher than generic prices, they decrease with market entry, and that a first-mover advantage consistently arises in oligopolies when accounting for general practitioners' prescription behaviors.

Original authors: Alberto Cavaliere, Giovanni Crea

Published 2026-09-10

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Alberto Cavaliere, Giovanni Crea

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

In the world of medicine, a drug's journey does not end when its patent expires. For decades, the standard expectation has been that once a new, expensive medication loses its legal monopoly, cheaper copies will flood the market, driving prices down for everyone. This is the logic of competition: more sellers, lower prices. Yet, in the complex landscape of pharmaceuticals, reality often defies simple logic. In many countries, the original brand-name drug remains significantly more expensive than its generic counterparts, even as the number of cheap copies increases. This phenomenon has puzzled economists and policymakers for years. It raises a fundamental question about how people make choices when faced with two medicines that are scientifically identical but carry different price tags and reputations. The answer lies not just in the chemistry of the pill, but in the psychology of the patient and the information they possess. Some patients know that the cheap copy works just as well as the expensive one, while others, often due to a lack of information or education, believe the original brand is superior, safer, or more effective, even when science says otherwise.

A team of researchers from the University of Pavia and the Università Cattolica del Sacro Cuore has built a new theoretical model to understand exactly how these choices play out in the marketplace. They focused on a specific scenario: patients paying for their own medication without the buffer of third-party insurance, a common situation in many parts of Europe. The researchers started by acknowledging that not all patients are the same. They divided the population into two groups based on their knowledge. The first group, the "informed" consumers, understands that a generic drug is chemically equivalent to the brand-name version. They care only about the price. The second group, the "uninformed" consumers, holds an optimistic but mistaken belief that the brand-name drug is of higher quality. They are willing to pay extra for the peace of mind that comes with a familiar name, even if it costs more. Crucially, the researchers found that this lack of information is not random; it is closely tied to income and education levels. Those with lower incomes and less education are more likely to hold these mistaken beliefs, while those with higher incomes and education are more likely to know the truth and choose the cheaper option.

Using this understanding of human behavior, the researchers simulated a market where a brand-name company sets its price first, knowing that generic competitors will enter the market later. In their model, the brand-name company acts as a leader, setting a high price to capture the profits from the uninformed patients who are willing to pay a premium for the brand. The generic companies, acting as followers, then set a lower price to attract the informed patients and the uninformed patients who are too poor to afford the brand. The results of this simulation challenge a long-standing economic theory known as the "Generics Competition Paradox." There are two versions of this paradox. The "hard" version suggests that as more generic companies enter the market, the brand-name drug actually becomes more expensive, because the brand company can ignore the competition and charge even more to its loyal, uninformed customers. The "soft" version suggests the brand price stays high but does not necessarily rise. The new research supports the "soft" version but goes further. It shows that while the brand-name drug remains more expensive than the generics, its price actually goes down as more generic competitors enter the market. The brand company cannot ignore the competition forever; as the number of cheap options grows, the brand is forced to lower its price to stay relevant, even if it stays higher than the generic price.

The study also looked at what happens when doctors get involved. In many real-world scenarios, patients do not choose their own medication; they rely on prescriptions from their general practitioners. The researchers found that if a significant number of doctors prefer to prescribe brand-name drugs—whether because they share the patients' misconceptions or because of industry influence—the market changes. In this scenario, the brand-name company gains a distinct advantage. The doctors' support effectively locks in a portion of the demand for the expensive drug, making it harder for generics to compete. Under these conditions, the brand-name company consistently earns more profit than all the generic companies combined, regardless of how many generic competitors enter the market. This suggests that in markets where medical professionals favor brands, the entry of generic drugs does not threaten the financial health of the original manufacturer, potentially allowing them to continue funding research and development.

The findings offer a clear explanation for why the spread of generic drugs varies so wildly across Europe. In countries like the United Kingdom and Germany, where generic usage is very high, the population tends to have higher levels of education and income, leading to a larger share of informed consumers who choose the cheaper option. In contrast, in countries like Italy and Greece, where generic usage is lower, the population has lower average education levels, resulting in a larger share of uninformed consumers who stick with the brand. The researchers suggest that simply mandating the use of generic names on prescriptions is not enough to change this behavior if the underlying information gap remains. Instead, the data implies that improving education levels and changing how medical students are taught to prescribe could be the most effective long-term strategies for increasing generic uptake. The study concludes that the market for off-patent drugs is driven by a mix of price, information, and trust, and that understanding these human factors is essential for predicting how competition will actually play out.

Technical Summary: Demand for Off-Patent Drugs and Sequential Price Competition with Heterogeneous Consumers

Problem Statement
The paper addresses the heterogeneity in generic drug uptake across European countries and the persistence of the "Generics Competition Paradox" (GCP). While empirical evidence suggests that brand-name drug prices often remain higher than generic prices even after patent expiry (the "soft" version of the GCP), there is debate regarding whether brand prices increase or decrease as the number of generic entrants grows (the "hard" version). Existing literature, particularly Kong (2009), explains the soft GCP in private insurance markets (e.g., the US) through market segmentation based on insurance coverage. However, theoretical contributions explaining these dynamics in public healthcare systems or for non-reimbursable drugs, where consumer information and education play a larger role, are lacking. Furthermore, the paper seeks to reconcile the "hard" GCP claim (that brand prices never decrease) with recent empirical findings showing a negative relationship between brand prices and the number of generic entrants.

Methodology
The authors develop a theoretical model of sequential price competition in a pharmaceutical market characterized by:

Consumer Heterogeneity: The market consists of a continuum of consumers with a willingness to pay (WTP) for quality, $\theta$ $θ$ , uniformly distributed. Consumers are divided into two groups based on information levels:
- Informed Consumers (IC): Possess higher education/income, understand bio-equivalence, and perceive brand and generic drugs as perfect substitutes ( $q_B = q_G$ ).
- Uninformed Consumers (UC): Possess lower education/income and hold "optimistic misperceptions," believing brand drugs offer superior therapeutic efficacy ( $q_E > q_B = q_G$ ).
Demand Specification: Demand is derived from utility maximization. UC demand for brands is driven by quality misperception, while IC demand is purely price-driven. The model assumes a "cut-off" value $\theta^*$ separating IC and UC, linking information disparity to income distribution.
Market Structure: The analysis proceeds in two stages:
- Duopoly: One brand-name firm (leader) and one generic firm (follower).
- Oligopoly: One brand-name firm and $n$ symmetric generic firms competing à la Cournot in the second stage.
Sequential Game: The brand-name firm sets its price first (Stackelberg leader), anticipating the generic firm's reaction. The model is extended to include a share of General Practitioners (GPs) who support brand-name drugs due to misperception or detailing, effectively reducing the pool of consumers willing to switch to generics.
Cost Assumptions: Marginal production costs are normalized to zero, assuming R&D costs are recovered during the patent period.

Key Contributions

Demand Specification: The paper specifies demand for off-patent drugs independently of health insurance, focusing on information disparity and perceived vertical differentiation. It posits that demand for generics (perceived as lower quality) comes from both informed consumers and the poorest uninformed consumers who cannot afford brands, while brand demand comes from uninformed consumers with sufficient income.
Reappraisal of the GCP: The model provides a theoretical explanation for the "soft" version of the GCP (brand prices remain higher) outside of private insurance systems. Crucially, it challenges the "hard" version by demonstrating that brand prices decrease as the number of generic entrants increases, aligning with recent empirical data from the US and Europe.
Dynamic Efficiency and Mover Advantages: The authors analyze whether a first-mover (brand) or second-mover (generic) advantage exists by comparing equilibrium profits. They extend the analysis to include physician prescribing behavior, a factor often overlooked in standard industrial organization models.

Results

Equilibrium Prices: In the sequential game, the brand-name firm sets a higher price ( $P^*_B$ ) than the generic firm ( $P^*_G$ ) to exploit the demand of uninformed consumers willing to pay a "brand premium."
Impact of Generic Entry: As the number of generic entrants ( $n$ ) increases, both the generic price and the brand price decrease. This confirms a negative relationship between brand prices and the number of generic firms, refuting the "hard" GCP. However, the brand price remains persistently higher than the generic price.
Mover Advantages:
- In a standard duopoly/oligopoly without physician intervention, a second-mover advantage for generic firms can arise, but only under specific conditions regarding the share of uninformed consumers ( $\theta^*$ ) and the lowest WTP ( $\theta$ ).
- When the model is extended to include a share of GPs who support brand-name drugs (reducing generic demand), the first-mover advantage for the brand-name firm always arises in an oligopoly. The brand firm's profits exceed the aggregate profits of all generic firms combined.
Role of Education and Information: The model suggests that markets with higher shares of informed consumers (correlated with higher education) will see lower brand premiums and higher generic uptake. Conversely, markets with high shares of uninformed consumers sustain higher brand prices.

Significance and Claims
The paper claims to offer a theoretical foundation for the observed heterogeneity in generic diffusion across Europe, linking it to consumer education and information levels rather than just policy mandates. It asserts that:

The "soft" GCP is a robust outcome of sequential competition with perceived vertical differentiation, even in public healthcare contexts.
The "hard" GCP (where brand prices rise or stay constant with more entry) is theoretically inconsistent with the model's results and recent empirical evidence.
Physician prescribing behavior acts as a critical barrier to generic uptake; when GPs favor brands, the brand firm secures a dominant first-mover advantage, potentially preserving dynamic efficiency (R&D incentives) by maintaining higher profits despite generic entry.
The model suggests that increasing generic uptake in the short term may require targeting physician education, while long-term structural changes depend on the education levels of the general population.

The authors conclude that their demand specification, which integrates information disparity and income, successfully explains the coexistence of high brand prices and increasing generic competition, providing a framework that aligns with empirical observations in both US and European markets.

More like this